⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6085098 | 1.00 | — | — | |
| SCHEMBL1192841 | 0.62 | — | — | |
| SCHEMBL5896876 | 0.60 | — | — | |
| SCHEMBL775459 | 0.57 | ALDH1A1 (0.35) | — | |
| SCHEMBL788339 | 0.57 | ALDH1A1 (0.35) | — | |
| SCHEMBL3956646 | 0.57 | ALDH1A1 (0.35) | — | |
| SCHEMBL2840915 | 0.57 | ALDH1A1 (0.32) | — | |
| SCHEMBL868850 | 0.57 | ALDH1A1 (0.35) | — | |
| SCHEMBL774380 | 0.57 | ALDH1A1 (0.35) | — | |
| SCHEMBL5307978 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200281873-A1 | Adamantane or Bicyclic Monoterpenoid Derivatives for Use in the Treatment of Leishmaniasis | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2020-09-10 | — | — | US | claimed |
| EP-3703673-A1 | ADAMANTANE OR BICYCLIC MONOTERPENOID DERIVATIVES FOR USE IN THE TREATMENT OF LEISHMANIASIS | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2020-09-09 | — | — | EP | claimed |
| EP-3476389-A1 | ADAMANTANE OR BICYCLIC MONOTERPENOID DERIVATIVES FOR USE IN THE TREATMENT OF LEISHMANIASIS | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2019-05-01 | — | — | EP | claimed |
| US-20170008893-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE COMPOUNDS | TERSERA THERAPEUTICS LLC | 2017-01-12 | — | — | US | claimed |
| EP-2137151-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 8-[{1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXY}-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE COMPOUNDS | OPKO HEALTH INC (US) | 2016-05-11 | — | — | EP | claimed |
| US-9260428-B2 | Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds | OPKO HEALTH, INC. (US) | 2016-02-16 | — | — | US | claimed |
| US-20140024834-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE COMPOUNDS | OPKO HEALTH, INC. (US) | 2014-01-23 | — | — | US | claimed |
| US-20100087426-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE COMPOUNDS | SCHERING CORPORATION | 2010-04-08 | — | — | US | claimed |
| EP-2137151-A2 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 8-Ý{1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXY}-METHYL¨-8-PHENYL-1,7-DIAZA-SPIROÝ4.5¨DECAN-2-ONE COMPOUNDS | SCHERING CORPORATION (US) | 2009-12-30 | — | — | EP | claimed |
| US-20090306442-A1 | OLIGOMERISATION CATALYST WITH PENDANT DONOR GROUPS | SASOL TECHNOLOGY (PTY) LIMITED (ZA) | 2009-12-10 | — | — | US | claimed |
| EP-2024305-A2 | OLIGOMERISATION CATALYST WITH PENDANT DONOR GROUPS | Sasol Technology (Pty) Ltd (ZA) | 2009-02-18 | — | — | EP | claimed |
| US-7456222-B2 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. (US) | 2008-11-25 | — | — | US | claimed |
| WO-2008118328-A2 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 8-[{1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXY}-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE COMPOUNDS | SCHERING CORPORATION (US) | 2008-10-02 | — | — | WO | claimed |
| WO-2007138545-A2 | OLIGOMERISATION CATALYST WITH PENDANT DONOR GROUPS | SASOL TECHNOLOGY (PTY) LIMITED (ZA) | 2007-12-06 | — | — | WO | claimed |
| US-6951961-B2 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2005-10-04 | — | — | US | claimed |
| EP-0194525-B1 | N-CARBAMOYL-AZOLES AND FUNGICIDES CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1988-08-10 | — | — | EP | claimed |
| EP-0194525-A2 | N-Carbamoyl-azoles and fungicides containing them | BASF Aktiengesellschaft (DE) | 1986-09-17 | — | — | EP | claimed |
| JP-7002762-A | — | — | None | — | — | JP | disclosed |
| US-5028610-A | Calcium Channel Blockers | SANKYO COMPANY LIMITED (JP) | 1991-07-02 | — | — | US | disclosed |
| EP-0194525-B1 | N-CARBAMOYL-AZOLES AND FUNGICIDES CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1988-08-10 | — | — | EP | disclosed |